Soluble CD40 ligand expression in stable atherosclerosis: A systematic review and meta-analysis
- 14 December 2020
- journal article
- review article
- Published by Elsevier BV in Atherosclerosis
- Vol. 319, 86-100
- https://doi.org/10.1016/j.atherosclerosis.2020.12.011
Abstract
No abstract availableKeywords
Funding Information
- Fundação para a Ciência e a Tecnologia
This publication has 75 references indexed in Scilit:
- CD40 ligand as a potential biomarker for atherosclerotic instabilityNeurological Research, 2013
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Platelet Activation in Patients with Atherosclerotic Renal Artery Stenosis Undergoing Stent RevascularizationClinical Journal of the American Society of Nephrology, 2011
- Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosisEuropean Journal of Clinical Nutrition, 2011
- Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring StudyAtherosclerosis, 2009
- Soluble CD40 Ligand as a Predictor of Coronary Artery Disease and Long-Term Clinical Outcomes in Stable Patients Undergoing Coronary AngiographyCardiology, 2007
- Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart diseaseClinical Cardiology, 2007
- The concentration of oxygen, lactate and glucose in the central veins, right heart, and pulmonary artery: a study in patients with pulmonary hypertensionCritical Care, 2007
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseJournal of the American College of Cardiology, 2003